Yang B, et al. - Given that a higher risk of brain metastasis (BM) development has been seen in patients with lung adenocarcinoma (ADC), and BM has been observed in association with genetic alterations, researchers retrospectively assessed the incidence of BM by stage and genetic alterations among 598 patients with lung ADC. Of these participants, the development of BM was detected in 97. They reported the occurrence of BM in nearly 16% of lung ADC patients, including 3% with stage I diseases. Across all stages of EGFR-mutant lung ADC, they found the presence of BM, whereas, BM was found only in advanced stages of ALK- or K-RAS-mutant lung ADC. Among never-smokers and among males, the identified risk factors for BM were EGFR mutations and K-RAS mutations, respectively.